A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
Latest Information Update: 15 Dec 2023
At a glance
Most Recent Events
- 08 Dec 2023 Status changed from not yet recruiting to completed.
- 19 Oct 2023 Planned End Date changed from 15 Dec 2023 to 9 Nov 2023.
- 19 Oct 2023 Planned primary completion date changed from 15 Dec 2023 to 9 Nov 2023.